DexCom, Inc. $DXCM Shares Bought by Public Employees Retirement System of Ohio

Public Employees Retirement System of Ohio grew its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 48.5% during the 1st quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 176,637 shares of the medical device company’s stock after purchasing an additional 57,722 shares during the period. Public Employees Retirement System of Ohio’s holdings in DexCom were worth $11,093,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Trust Co. of Vermont increased its holdings in shares of DexCom by 14.8% in the 4th quarter. Trust Co. of Vermont now owns 1,122 shares of the medical device company’s stock valued at $74,000 after purchasing an additional 145 shares in the last quarter. V Square Quantitative Management LLC lifted its stake in shares of DexCom by 1.8% in the first quarter. V Square Quantitative Management LLC now owns 9,618 shares of the medical device company’s stock valued at $604,000 after purchasing an additional 172 shares during the period. Essex Financial Services Inc. boosted its holdings in DexCom by 5.7% during the first quarter. Essex Financial Services Inc. now owns 3,256 shares of the medical device company’s stock worth $204,000 after buying an additional 175 shares in the last quarter. IFP Advisors Inc boosted its holdings in DexCom by 24.7% during the third quarter. IFP Advisors Inc now owns 900 shares of the medical device company’s stock worth $61,000 after buying an additional 178 shares in the last quarter. Finally, Keel Point LLC boosted its holdings in DexCom by 3.1% during the fourth quarter. Keel Point LLC now owns 6,473 shares of the medical device company’s stock worth $430,000 after buying an additional 193 shares in the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on DXCM. Barclays reaffirmed an “underweight” rating and issued a $64.00 target price (down from $67.00) on shares of DexCom in a report on Monday, May 18th. Deutsche Bank Aktiengesellschaft assumed coverage on DexCom in a research note on Tuesday, June 23rd. They set a “buy” rating and a $86.00 price target on the stock. Bank of America lowered their price target on DexCom from $100.00 to $80.00 and set a “buy” rating on the stock in a report on Monday, May 18th. Sanford C. Bernstein set a $77.00 price objective on DexCom in a research note on Friday, May 1st. Finally, Raymond James Financial reaffirmed a “strong-buy” rating and issued a $91.00 price objective on shares of DexCom in a research note on Monday, June 8th. Two analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, DexCom has an average rating of “Moderate Buy” and a consensus price target of $85.36.

Insider Activity

In other DexCom news, insider Kevin R. Sayer sold 26,759 shares of the stock in a transaction on Thursday, May 21st. The stock was sold at an average price of $72.00, for a total transaction of $1,926,648.00. Following the sale, the insider owned 382,482 shares in the company, valued at approximately $27,538,704. This represents a 6.54% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Jon Coleman sold 4,912 shares of the firm’s stock in a transaction on Wednesday, June 3rd. The stock was sold at an average price of $73.00, for a total value of $358,576.00. Following the transaction, the executive vice president directly owned 100,361 shares of the company’s stock, valued at $7,326,353. The trade was a 4.67% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 71,750 shares of company stock worth $5,163,241. 0.28% of the stock is owned by corporate insiders.

DexCom Stock Performance

NASDAQ:DXCM opened at $71.54 on Monday. The company has a current ratio of 1.95, a quick ratio of 1.64 and a debt-to-equity ratio of 0.42. The company has a market capitalization of $27.61 billion, a P/E ratio of 30.57, a price-to-earnings-growth ratio of 1.18 and a beta of 1.45. The firm has a 50-day moving average price of $72.46 and a two-hundred day moving average price of $68.95. DexCom, Inc. has a twelve month low of $54.11 and a twelve month high of $89.98.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, April 30th. The medical device company reported $0.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.47 by $0.09. The company had revenue of $1.19 billion for the quarter, compared to the consensus estimate of $1.17 billion. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The company’s revenue for the quarter was up 15.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.32 earnings per share. As a group, research analysts expect that DexCom, Inc. will post 2.57 earnings per share for the current fiscal year.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.